These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30009261)

  • 1. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance.
    Matsushita T; Kobayashi T; Mizumaki K; Kano M; Sawada T; Tennichi M; Okamura A; Hamaguchi Y; Iwakura Y; Hasegawa M; Fujimoto M; Takehara K
    Sci Adv; 2018 Jul; 4(7):eaas9944. PubMed ID: 30009261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-producing B-cell balance associates with skin fibrosis in patients with systemic sclerosis.
    Horii M; Fushida N; Ikeda T; Oishi K; Hamaguchi Y; Ikawa Y; Komuro A; Matsushita T
    J Dermatol; 2022 Oct; 49(10):1012-1019. PubMed ID: 35751840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a novel CD30
    Higashioka K; Kikushige Y; Ayano M; Kimoto Y; Mitoma H; Kikukawa M; Akahoshi M; Arinobu Y; Horiuchi T; Akashi K; Niiro H
    Clin Exp Immunol; 2020 Sep; 201(3):233-243. PubMed ID: 32538493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effector and regulatory B-cell imbalance in systemic sclerosis: cooperation or competition?
    Liu M
    Clin Rheumatol; 2024 Sep; 43(9):2783-2789. PubMed ID: 39080112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory and effector B cells: Friends or foes?
    Matsushita T
    J Dermatol Sci; 2019 Jan; 93(1):2-7. PubMed ID: 30514664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
    Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients.
    Aravena O; Ferrier A; Menon M; Mauri C; Aguillón JC; Soto L; Catalán D
    Arthritis Res Ther; 2017 Jan; 19(1):8. PubMed ID: 28103916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
    Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
    J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis.
    François A; Chatelus E; Wachsmann D; Sibilia J; Bahram S; Alsaleh G; Gottenberg JE
    Arthritis Res Ther; 2013 Oct; 15(5):R168. PubMed ID: 24289101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential roles of interleukin-17A in the development of skin fibrosis in mice.
    Okamoto Y; Hasegawa M; Matsushita T; Hamaguchi Y; Huu DL; Iwakura Y; Fujimoto M; Takehara K
    Arthritis Rheum; 2012 Nov; 64(11):3726-35. PubMed ID: 22833167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis.
    François A; Gombault A; Villeret B; Alsaleh G; Fanny M; Gasse P; Adam SM; Crestani B; Sibilia J; Schneider P; Bahram S; Quesniaux V; Ryffel B; Wachsmann D; Gottenberg JE; Couillin I
    J Autoimmun; 2015 Jan; 56():1-11. PubMed ID: 25441030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8
    Kobayashi T; Oishi K; Okamura A; Maeda S; Komuro A; Hamaguchi Y; Fujimoto M; Takehara K; Matsushita T
    J Invest Dermatol; 2019 Jul; 139(7):1535-1544.e1. PubMed ID: 30836062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
    Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
    Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell activating factor (BAFF) selects IL-10
    Ma N; Zhang Y; Liu Q; Wang Z; Liu X; Zhu G; Yu D; Han G; Chen G; Hou C; Wang T; Ma Y; Shen B; Li Y; Xiao H; Wang R
    Mol Immunol; 2017 May; 85():18-26. PubMed ID: 28199852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice.
    Lei L; Zhong XN; He ZY; Zhao C; Sun XJ
    Cell Biol Int; 2015 Apr; 39(4):388-99. PubMed ID: 25492803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD22 and CD72 contribute to the development of scleroderma in a murine model.
    Zhao C; Matsushita T; Ha Nguyen VT; Tennichi M; Fujimoto M; Takehara K; Hamaguchi Y
    J Dermatol Sci; 2020 Jan; 97(1):66-76. PubMed ID: 31883832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of TLR7 and TLR9 in the Pathogenesis of Systemic Sclerosis.
    Wang C; Oishi K; Kobayashi T; Fujii K; Horii M; Fushida N; Kitano T; Maeda S; Ikawa Y; Komuro A; Hamaguchi Y; Matsushita T
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice.
    Matsushita T; Fujimoto M; Hasegawa M; Matsushita Y; Komura K; Ogawa F; Watanabe R; Takehara K; Sato S
    J Invest Dermatol; 2007 Dec; 127(12):2772-80. PubMed ID: 17581616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
    Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
    Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.